The syntrophins and a-dystrobrevin form a subcomplex with dystrophin at the skeletal muscle membrane, and are also highly concentrated at the neuromuscular synapse. Here we demonstrate that the different syntrophins and a-dystrobrevin isoforms have distinct expression patterns during human skeletal muscle development, and are differentially affected by loss of dystrophin anchorage and denervation in human neuromuscular disease. During normal fetal development, and in Duchenne muscular dystrophy and denervation disorders, a1-syntrophin and a-dystrobrevin are absent or markedly reduced at the sarcolemmal membrane. b1-Syntrophin is the predominant syntrophin isoform expressed at the muscle membrane during development, and it undergoes upregulation in response to loss of a1-syntrophin in Duchenne muscular dystrophy and in denervation. Upregulation of b1-syntrophin in neuromuscular disorders is associated with re-expression of the fetal nicotinic acetylcholine receptor g-subunit, cardiac actin, and neonatal myosin, suggesting reversion of muscle fibers to an immature phenotype. We show that denervation specifically affects expression of the syntrophindystrobrevin subcomplex and does not affect levels or localization of other members of the dystrophin-associated protein complex. Our results confirm that dystrophin is required for anchorage of the syntrophin-dystrobrevin subcomplex and suggest that expression of the syntrophin-dystrobrevin complex may be independently regulated through neuromuscular transmission.
INTRODUCTION
The syntrophin and dystrobrevin multigene families were originally identified through their association with postsynaptic membranes from Torpedo electric organs (1) (2) (3) . In mammalian skeletal muscle, the syntrophins and dystrobrevins are highly concentrated at the postsynaptic membrane and form part of a cytoplasmic subcomplex within the dystrophinassociated protein complex (DAPC) at the sarcolemmal membrane (4, 5) . Mutations in members of the DAPC result in various forms of muscular dystrophies (6) , the most common of which are Duchenne and Becker muscular dystrophies, due to mutations within the gene encoding dystrophin (7) .
All syntrophin isoforms share similar domain organization; pleckstrin homology domains, a PDZ protein-interaction domain, and a carboxyl-terminal syntrophin unique domain (8, 9) . Through these conserved domains, the syntrophins interact with several signaling and structural molecules including phosphatidylinositol 4,5-bisphosphate (10), neuronal nitric oxide synthase (nNOS) (11) , the water channel aquaporin-4 (AQP4) (12) (13) (14) , voltage-activated sodium channels (15) , several kinases (16) (17) (18) , and the dystrophin-related proteins (dystrophin, utrophin and dystrobrevins) (19) (20) (21) . The dystrobrevins are encoded by 2 separate genes, a-dystrobrevin (aDB) and b-dystrobrevin. Alternate splicing of aDB generates 3 musclespecific isoforms (aDB1, 2, and 3) (22, 23) . The 2 larger isoforms, aDB1 and aDB2, contain the syntrophin and dystrophin-binding sites (24) (25) (26) .
In both dystrophinopathy patients and mdx mice, there is reduced expression of a1-syntrophin (27) (28) (29) , accompanied by a decrease in nNOS levels (30) and a marked reduction of AQP4 (31, 32) . Knockout models of a1-syntrophin and aDB have been studied in detail (13, 14, (33) (34) (35) (36) . a1-Syntrophin 2/2 mice display neither a dystrophic nor myopathic phenotype. Expression of the DAPC is normal with the exception of nNOS (13) and AQP4 (14) , which are lost from the muscle membrane. However, a1-syntrophin 2/2 mice exhibit aberrant formation of neuromuscular junctions (NMJs) deficient in utrophin and with reduced nicotinic acetylcholine receptor (nAChR) density (13) . aDB 2/2 mice display a cardiomyopathy (36) with mild muscular dystrophy. The dystrophic phenotype observed in aDB 2/2 mice is not associated with loss of the DAPC, although a slight reduction in a1-syntrophin is observed (26) . Consistent with its expression at the NMJ, the aDB 2/2 shows abnormal formation of NMJs with abnormally distributed and unstable nAChR clusters (37) .
Preliminary work from our laboratory highlighted apparent differences in expression of the syntrophins and aDB between mature human and mouse skeletal muscle (38, 39) . In particular, both b2-syntrophin and aDB1 are restricted exclusively to the postsynaptic membrane of the NMJ in mature mouse muscle but show significant expression at the sarcolemmal membrane in human skeletal muscle. Our laboratory has also demonstrated isolated immunohistochemical abnormalities within the syntrophin-dystrobrevin subcomplex in a group of human patients presenting with myopathies of unknown etiology (39) . However, the role of the syntrophin-dystrobrevin subcomplex in the pathogenesis of dystrophinopathy and other human neuromuscular disorders is unknown. Therefore, we have defined the expression of the syntrophins and aDB isoforms throughout development in human skeletal muscle using isoform-specific antibodies. We have also explored the influence of dystrophin anchorage and innervation on the expression of the syntrophins and a-dystrobrevin in human skeletal muscle. Immunohistochemical analysis of the developmental expression of a1-, b1-, and b2-syntrophin, adystrobrevin-1 and -2, and dystrophin in human skeletal muscle. Frozen sections of human (19 weeks gestation [19 w.g.] , birth, 26 days postnatal and 9 months old) skeletal muscle were stained with antibodies for a1-syntrophin (a1-SYN), b1-syntrophin (b1-SYN), b2-syntrophin (b2-SYN), a-dystrobrevin-1 (aDB1), a-dystrobrevin-2 (aDB2), and dystrophin (DYS). Fiber typing was determined using antibodies specific for fast and slow myosin heavy chains. Fast fibers are indicated with an arrow and slow fibers with an asterisk. Scale bar = 20 mm.
MATERIALS AND METHODS

Biopsy and Clinical Data
Muscle biopsies were obtained through archived material (1984) (1985) (1986) (1987) (1988) (1989) (1990) (1991) (1992) (1993) (1994) (1995) (1996) (1997) (1998) (1999) (2000) (2001) (2002) at the University of Sydney and the Children's Hospital at Westmead. The 5 ''control'' biopsies and 20 ''developmental'' biopsies were classified as ''control muscle'' when there were no ultrastructural changes identified by light or electron microscopy, and all standard histologic stains were normal, or they were obtained from patients without muscle disorders. ''Denervation'' patients were defined as patients with a defined denervation disorder: 4 spinal muscular atrophy patients (exon 7 and 8 deletions), 1 amyotrophic lateral sclerosis, 1 distal spinal muscular atrophy, and 1 giant axonal neuropathy. Duchenne muscular dystrophy patients with characterized dystrophin gene mutations were also studied (n = 7). These studies were approved by the Ethics committees of the Children's Hospital at Westmead and the University of Sydney.
Antibodies
Syntrophin:
Polyclonal rabbit antibodies were raised against isoform-specific peptides and characterized by Peters et al (5, 40) ; SYN17 (a1-syntrophin), SYN28 (b2-syntrophin), and SYN35 or SYN37 (b1-syntrophin).
Dystrobrevin:
Rabbit polyclonal antibodies specific for a-dystrobrevin-1 (DB670) and a-dystrobrevin-2 (DB2) were raised against isoform-specific sequences and characterized by Peters et al (38) .
Acetylcholine Receptor:
Monoclonal antibodies recognizing the fetal nAChR g-subunit (MAB322; Chemicon, Temecula, CA) and a-subunit (mAb35; University of Iowa Hybridoma Bank) (41) .
Myosin:
Fiber typing was determined using antibodies raised against slow myosin (MAB1628; Chemicon), developmental myosin heavy chain (NCL-MHCd) and neonatal myosin heavy chain (NCL-MHCn) obtained from Novocastra Laboratories Ltd. (Newcastle upon Tyne, UK), and fast myosin (MY32) obtained from Sigma-Aldrich (St. Louis, MO).
DAPC:
Monoclonal antibodies recognizing dystrophin (NCL-DYS1 [rod-domain], NCL-DYS2 [C-terminus], and NCL-DYS3 [N-terminus]), utrophin (NCL-DRP2), b-dystroglycan (NCL-b-DG), the sarcoglycans (a-, b-, g-and d-), and laminin a2 (NCL-Merosin) were obtained from Novocastra Laboratories Ltd. Polyclonal DYS6-10, raised against a peptide encoded by 6,000 to 10,000 base pairs of the dystrophin mRNA ORF, was kindly donated by Dr. Louis Kunkel (Boston, MA). Monoclonal anti-a-dystroglycan (clone VIA4-1) was obtained from Upstate Biotechnology (Lake Placid, NY). A rabbit polyclonal antibody raised against sarcospan was generously provided by Dr. Louis Kunkel. Monoclonal anti-laminin a2 (MAB1922) was obtained from Chemicon, and clone 4H8-2 obtained from Alexis (San Diego, CA).
Other Antibodies: Membranes were probed for a1-syntrophin (a1-SYN). Coomassie staining of the membrane demonstrates total myosin loading. (B) Membranes were sectioned and probed for b1-syntrophin (b1-SYN), neonatal myosin heavy chain (nMyHC), and fast myosin heavy chain (fMyHC). The relative proportion of fast-fibers (as b1-syntrophin is normally fast fiber restricted) is shown by probing with a fast myosin antibody (MY32) that recognizes both fMyHC and nMyHC.
anti-rabbit antibodies were obtained from Jackson Immunoresearch Laboratories Inc. (West Grove, PA).
Immunohistochemistry
Frozen muscle biopsy samples were cut into 8-mm cryosections. Staining was performed on poly-L-lysine-coated microscope slides (Menzel-Gläser, Braunschweig, Germany) as described previously (39) . The specificity of syntrophin and a-dystrobrevin antibodies was tested by preincubation with antibody peptides. Fluorescent images were captured using a Leica SP2 scanning confocal microscope. In all panels, for each antibody, control and patient samples were imaged under identical conditions to enable comparison of fluorescent intensities.
Western Blotting
Immunoblotting was carried out as described previously (42) . Equal sample loading was evaluated using myosin band intensity on mini-gels. Samples adjusted for myosin loading were separated by SDS-PAGE, transferred to polyvinylidene fluoride (PVDF) membranes (Millipore, Billerica MA), probed with indicated antibodies and developed with ECL chemiluminescent reagents (Amersham Biosciences). Specificity of antibodies raised against a1-syntrophin and b1-syntrophin were tested by preincubation with antibody peptides (data not shown).
Bioinformatics
Homology searches for human b1-syntrophin were conducted using the BLASTN program accessible through the National Center for Biotechnology Information home page (www.ncbi.nlm.nih.gov/BLAST/). Prediction of potential phosphorylation sites was done under high stringency using Scansite 2.0 (http://scansite.mit.edu), a computational tool built on experimental binding and/or substrate information from oriented peptide library screening and phage display experiments (43) .
RESULTS
Developmental Expression of the Syntrophins and a-Dystrobrevin in Skeletal Muscle
We examined the developmental expression of a1-, b1-, and b2-syntrophin, and a-dystrobrevin-1 and -2, in human skeletal muscle (from 14 weeks gestation through 20 years of age). Results from a subset of developmental time-points are presented in Figure 1 . 
, and fast myosin (MY32). Negative staining was observed for dystrophin in DMD muscle, with occasional revertant fibers. a1-syntrophin, a-DB1, and a-DB2 are expressed at reduced levels in DMD muscle and localize predominantly within the cytoplasm. Spectrin staining confirms membrane integrity within the samples. Scale bar = 80 mm q 2005 American Association of Neuropathologists, Inc.
The developmental expression of the syntrophins and adystrobrevin was compared with that of known molecular markers for muscle and NMJ development, such as the developmental myosin heavy chains (MyHC) and the embryonic nAChR-g subunit. By immunohistochemistry (IHC), the 3 syntrophins were detected at all developmental ages studied. a1-Syntrophin was predominantly expressed in the cytoplasm before birth, localizing to the plasma membrane postnatally (Fig. 1, a1-SYN) .
b1-Syntrophin localized to the sarcolemmal membrane of all fiber types throughout fetal and early postnatal development (Fig. 1, b1-SYN) . b1-syntrophin localization to the sarcolemmal membrane of all fibers coincided with neonatal MyHC expression in those fibers (Fig. 2B ). Developmental MyHC was expressed at significant levels only in early fetal development (before 25 weeks gestation) (data not shown). Neonatal MyHC expression in humans was observed at 19 weeks gestation through to the early newborn period, and was rapidly downregulated by 5 months (Fig. 2B ). By 9 months of age, fibers have dedicated fast or slow MyHC expression, and b1-syntrophin expression became restricted to the sarcolemmal membrane of fast fibers. Fiber typing was determined by costaining with fast or slow myosin heavy chain-specific antibodies.
b2-Syntrophin localized to the cytoplasm during human fetal development, with variability in staining intensity between fibers (Fig. 1, b2-SYN) . In the early postnatal period and in mature muscle, b2-syntrophin specifically labeled the sarcolemmal membrane of slow fibers, with diffuse cytoplasmic staining in fast fibers.
aDB2 was the predominant isoform expressed prior to birth and localized to the sarcolemma from 19 weeks gestation (Fig. 1, aDB2) . aDB1 was detected only weakly at the muscle membrane prior to birth, with increasing levels of expression at the muscle membrane postnatally (Fig. 1, aDB1) . Dystrophin was detected at the sarcolemmal membrane at all ages studied, using 3 antibodies recognizing distinct regions of dystrophin (NCL-DYS1, 2, 3) (Fig. 1, NCL-DYS3 shown) .
Immunoblot analysis of whole muscle lysates derived from biopsy samples (19 weeks gestation through 8 years) revealed a transition from a single band of a1-syntrophin, to a doublet band appearing around birth, at the same time that a1-syntrophin becomes localized to the sarcolemma and NMJ ( Fig. 2A) .
In humans, b1-syntrophin was detected predominantly as a single band at~59 kDa at 19 weeks gestation, and as a doublet from 25 weeks gestation (Fig. 2B ). An additional 48-kDa anti-b1 syntrophin-immunoreactive band was clearly detected in human samples at all ages. Specificity of antibody binding was verified using the blocking peptide (data not shown), suggesting this band is specifically recognized by the polyclonal sera and likely represents an additional b1-syntrophin isoform.
Levels of total a1-syntrophin remained fairly constant throughout development. In contrast, higher levels of b1-syntrophin are observed during early development, coincident with neonatal MyHC expression (Fig. 2B) . Analysis of dystrophin expression throughout development in human muscle demonstrated low levels before 25 weeks gestation, after which time it was expressed at mature levels (results not shown), consistent with previous reports (44) . Antibodies raised against b2-syntrophin and a-dystrobrevin did not work by Western analysis and therefore these proteins were studied in detail by IHC only (Fig. 1) . FIGURE 4 . b1-Syntrophin is upregulated in response to decreased levels of a1-syntrophin in DMD muscle. Immunoblot analysis of skeletal muscle biopsy samples from 2 patients with Duchenne muscular dystrophy (D 1 and D 2 ) and agematched controls (C 1 and C 2 ). Duplicate membranes were sectioned and probed for dystrophin (DYS), a1-syntrophin (a1-SYN), or b1-syntrophin (b1-SYN). Neonatal myosin (nMyHC) expression reflects levels of immature, regenerating fibers. Levels of fast myosin expression (fMyHC) was examined using MY32, which also detects neonatal myosin. Spectrin (Spect) provides a control for loading of submembranous cytoskeleton. Coomassie-stained PVDF membranes shows total myosin loading.
Expression of the Syntrophin-Dystrobrevin Subcomplex in Human Neuromuscular Disease Duchenne Muscular Dystrophy (DMD):
To study the role of dystrophin-anchorage on the localization of the syntrophin-dystrobrevin subcomplex, we analyzed individual syntrophin and a-dystrobrevin isoforms in DMD patients by IHC (Fig. 3) and Western blot (Fig. 4) . All images shown are representative of results seen for all DMD patients (n = 7) with both IHC and Western blot. The syntrophins (a1-, b1-, and b2-) were detectable by IHC in all DMD patients studied. However, a1-syntrophin was present at decreased levels at the membrane of all fibers, with increased expression within the cytoplasm (Fig. 3, a1-SYN) . Both b1-and b2-syntrophin showed loss of fiber-type specificity, with membrane localization in both fast and slow fibers (Fig. 3, b1-SYN and b2-SYN) . Interestingly, despite detectable levels of a1-syntrophin, AQP4 was absent from the sarcolemma in all DMD patients studied, in agreement with previous reports (29, 32) (data not shown). In all DMD patients, nAChR-g was detected at moderate levels in most fibers, similar to that seen in mdx mice (45) , with occasional groups of fibers staining more intensely (data not shown). The nAChR-g-positive fibers also expressed developmental MyHC, neonatal MyHC, and cardiac actin (Table, data not shown) and there was patchy staining with spectrin, suggesting that these fibers had undergone necrosis (Fig. 3, spectrin) (46) .
In all DMD patients, both aDB-1 and -2 showed a reduction in sarcolemmal expression in all fibers, with some fibers showing increased cytoplasmic staining for aDB2 (Fig.  3, aDB1 and aDB2) . In contrast, utrophin showed increased expression at the sarcolemma of all fibers in all DMD patients, in addition to staining at the NMJ (data not shown).
Dystrophin was undetectable by Western blot in DMD patients (Fig. 4) , confirming disease status, although occasional revertant fibers were detected by IHC (Fig. 3, DYS) . Total a1-syntrophin levels were lower in DMD patients compared with control samples corresponding with the decreased expression detected by IHC. The cytoplasmic localization of a1-syntrophin in DMD patients did not correspond with reversion to the single a1-syntrophin band on immunoblot that was observed in normal fetal muscle (Fig. 4) . In contrast, elevated levels of the 58/59-kDa doublet detected for b1-syntrophin were observed, coincident with increased expression of neonatal MyHC (Fig. 4, nMyHC) .
Denervation Disorders:
To explore the role of innervation in the localization and isoform-specific expression of the syntrophins, we performed IHC and Western blot analysis of muscle biopsies from patients with defined denervation disorders: spinal muscular atrophy, distal spinal muscular atrophy, giant axonal neuropathy, and juvenile amyotrophic lateral sclerosis. All biopsies studied (n = 7) exhibited 2 populations of fibers: hypertrophied innervated fibers and atrophied denervated fibers (47) . Atrophied fibers observed in denervated muscle are thought to result from alterations in expression levels of nerve trophic factor(s) (48) such as cardiotrophin (49, 50) , with reported upregulation of both apoptosis-promoting and apoptosis-inhibiting proteins, such as bax, caspase, bcl-2, bcl-xL (51-53). Increased proteolysis targeting sarcomeric protein degradation contributes to fiber atrophy (54, 55) and is accompanied by a reduction in the mean number of myonuclei per fiber and an increase in apoptotic (TUNEL-positive) nuclei (56) .
Denervated fibers have an immature phenotype characterized by expression of neonatal myosin heavy chain, cardiac actin, and the embryonic nAChR-g subunit.
Analysis of patient biopsy samples with antibodies raised against slow myosin (slow MyHC), fast myosin (MY32) (data not shown), developmental myosin (NCL-MHCd), and neonatal myosin (NCL-MHCn) demonstrated that neonatal MyHC was the predominant MyHC expressed in denervated fibers (Table; Fig. 5, nMyHC) .
No fibers stained positively for developmental MyHC (data not shown). Denervated fibers also expressed cardiac actin and the embryonic nAChR g-subunit (Fig. 5 , cardiac actin and AChRg-subunit) consistent with an immature phenotype. The increased sarcolemmal expression of the nAChR-g subunit in denervated fibers is similar to reports in rodent denervation studies (57, 58) . In all patients, slow MyHC was the predominant isoform expressed in the larger, innervated fibers (Fig. 6, sMyHC) , although a subset of innervated fibers in the giant axonal neuropathy patient expressed both fast and slow MyHC isoforms.
Denervation Specifically Affects Expression of Syntrophin, a-Dystrobrevin, and AQP4
In all patient samples, a1-syntrophin was present at the sarcolemma of large, innervated fibers but was absent from the sarcolemma of atrophied denervated fibers; in these fibers, a1-syntrophin localized to the cytoplasm (Fig. 6, a1-SYN) .
AQP4 was also lost from the sarcolemma of the denervated fibers in all neurogenic disorders, likely secondary to loss of a1-syntrophin (data not shown). AQP4, which is usually predominantly expressed in fast fibers, was not detected in the large innervated fibers expressing slow myosin (not shown). Double labeling of biopsy samples with antibodies recognizing b1-syntrophin (SYN35) and MyHC isoforms demonstrated membrane staining of b1-syntrophin in all fibers (both neonatal MyHC-positive and slow MyHC-positive) (Fig. 6, b1-SYN) . This is consistent with loss of fast fiberspecific expression typically observed in mature muscle, and reversion to developmental expression patterns. However, b2-syntrophin expression remained specific to slow fibers, in this case, the larger innervated fibers (Fig. 6, b2-SYN) .
The cytoplasmic localization of a1-syntrophin in denervated fibers mimicked expression patterns observed during fetal development. On Western blot analysis, an a1-syntrophin doublet was detected in all patient and control samples, although relative levels of the upper and lower a1-syntrophin doublet bands varied between samples (Fig. 7A) .
Levels of b1-syntrophin were increased in muscle samples derived from patients with denervation disorders (Fig. 7B,  lanes 3-7) , compared with age-matched controls (Fig. 7B,  lanes 1-2, 8-9 ), in agreement with immunohistochemical results. These results demonstrate upregulation of b1-syntrophin levels in patients with denervation disorders, likely due, in part, to loss of fast fiber-type specificity and to expression in all fibers.
a-Dystrobrevin-1 was present in both the cytoplasm and at the sarcolemma of large, innervated fibers, but was absent from the sarcolemma in denervated fibers. aDB2 was only detected at the sarcolemma of large, innervated fibers (Table, data not shown). In all cases, membrane integrity was confirmed by staining for b-spectrin (Fig. 5, spectrin) . 
Dystrophin, Utrophin, and DAPC Components Are Normally Expressed in Denervated Fibers
Dystrophin was expressed at normal levels at the sarcolemma of both denervated and innervated fibers (Fig. 8 , DYS) using antibodies to 3 different epitopes across the dystrophin protein (NCL-DYS1, 2, 3).
Utrophin stained occasional NMJs of innervated fibers but was not detected at the sarcolemma of either innervated or denervated fibers (Table, data not shown). All other members of the DAPC (laminin a2, a-dystroglycan, b-dystroglycan, the sarcoglycans [a-, b-, g-, d-] and sarcospan) were expressed at normal levels at the sarcolemma (Fig. 8) . Thus, denervation differentially affects the localization of the syntrophindystrobrevin subcomplex, compared to other members of the DAPC.
DISCUSSION
The present study demonstrates that the members of the syntrophin-dystrobrevin subcomplex have distinct expression patterns during development and are differentially affected by loss of dystrophin anchorage and denervation.
Syntrophins Show Distinct Patterns of Expression throughout Development
Although the dystrophin-associated protein complex has been studied extensively throughout development, very little attention has been focused on the syntrophin-dystrobrevin subcomplex. In this study, we have demonstrated that syntrophins and a-dystrobrevin show unique patterns of expression in skeletal muscle throughout development, with notable differences between humans and mice.
b1-Syntrophin is the predominant syntrophin isoform expressed at the sarcolemmal membrane during early development in both human and mouse muscle (59) . The membrane localization of b1-syntrophin coincides with neonatal MyHC expression during development, with fast MyHC in adult human muscle, and specifically with fast MyHC Type IIB fibers in adult mouse muscle (5) . A developmental role for b1-syntrophin is supported by recent microarray studies in differentiating C2C12 cells (60) . Expression of b1-syntrophin was markedly increased upon withdrawal from the cell cycle and myoblast fusion compared with levels of a1-syntrophin and a-dystrobrevin. Increases in b1-syntrophin expression (~3-to 5-fold) during early myotube development was coincident with upregulation in expression FIGURE 6. Syntrophin expression is specifically altered in denervated skeletal muscle fibers. Frozen skeletal muscle sections from control (CON), spinal muscular atrophy (SMA), giant axonal neuropathy (GAN), and juvenile amyotrophic lateral sclerosis (ALS) were stained with antibodies recognizing each syntrophin isoform (a1-SYN, b1-SYN, and b2-SYN) as well as an antibody raised against slow myosin heavy chain (sMyHC). a1-syntrophin is lost from the sarcolemmal membrane of small, denervated fibers; b1-syntrophin is expressed in both the denervated and innervated fibers; b2-syntrophin is expressed predominantly in the large, slow fibers. of cardiac and skeletal actin; embryonic, perinatal, and adult MyHCs, as well as other members of the sarcoglycan complex known to have a role in muscle development (60) .
In mice, a1-syntrophin expression at the sarcolemmal and postsynaptic membranes is present at birth (59) . Further analysis has shown similar expression of a1-syntrophin at the membrane and NMJ at embryonic day 14.5, approximately 1 day after muscle innervation (Banks GB, Noakes PG, personal communication). In contrast, during human skeletal muscle development, a1-syntrophin localizes predominantly within the cytoplasm until late gestation/birth, when it becomes localized to the muscle membrane and postsynaptic region of the NMJ. Muscle innervation occurs at 8 to 9 weeks of gestation (61) in humans, and therefore does not obviously influence the membrane localization of a1-syntrophin.
b2-syntrophin and aDB1 are found almost exclusively at the NMJ and perisynaptic membrane regions in adult mouse muscle (38, 40) . This was not the case in mature human muscle where, in addition to labeling of the NMJ, membrane labeling for b2-syntrophin (slow fibers) and aDB1 (all fibers) was clearly observed. aDB2 is the predominant a-dystrobrevin isoform expressed at the sarcolemmal membrane during development in human skeletal muscle.
Western analysis of a1-and b1-syntrophin expression over a developmental time course showed the appearance of multiple bands. For a1-syntrophin, we observed a transition from a single band to a doublet band appearing around birth, at which time a1-syntrophin becomes localized to the sarcolemma and NMJ. For b1-syntrophin, we observed a shift from a single b1-syntrophin band at 19 weeks gestation, to doublet 58/59 kDa bands by 36 weeks gestation. An additional b1-syntrophin immunoreactive band, specifically blocked by the peptide-antigen, was also detected migrating at 48 kDa. BLASTP homology searches confirmed the sequence specificity of the a1-and b1-syntrophin antibody peptide sequences.
Previous studies have identified three predominant b1-syntrophin transcripts expressed in human muscle tissue (62) , suggesting that additional bands may represent alternative splice forms. However, the a1-syntrophin sequence predicts only a single open reading frame, with no alternately spliced isoforms reported. Studies in Torpedo have demonstrated that ''syntrophin'' is phosphorylated endogenously on tyrosine and serine residues (63) , and multiple putative phosphorylation sites ($ 90% confidence interval) are predicted throughout each of the human, murine, and Torpedo syntrophin sequences (Scansite 2.0 software). a1-Syntrophin has been shown to act as a substrate for the stress-activated kinase SAPK3 (also known as ERK6) (16) and calcium calmodulin-dependent protein kinase II (64) (65) (66) . This raises the possibility that a1-and b1-syntrophin doublet bands at distinct time-points during development may reflect alterations in their phosphorylation status.
Dystrophin Is Required for Anchorage of the Syntrophin-Dystrobrevin Subcomplex
Dystrophin plays a critical role at the sarcolemma for membrane stability and as a scaffold to anchor other members of the dystrophin complex. The absence of dystrophin in mice and humans results in a severe reduction in membrane expression of DAPC components (67, 68) . In our study, a1-syntrophin, aDB1, and aDB2 were expressed at reduced levels in muscle from DMD patients and localize predominantly within the cytoplasm. These results suggest a1-syntrophin, aDB1, and aDB2 are dependent on dystrophin for normal expression at the sarcolemma. In DMD biopsy samples, both b1-and b2-syntrophin lost their fiber-type specificity and were expressed in both fast and slow fibers. Upregulation and loss of fast-fiber restricted expression of b1-syntrophin was accompanied by re-expression of neonatal MyHC and nAChR-g. The results from this study are in contrast with previous reports using pan-specific syntrophin antibody (mAb SYN1351), which showed an absence of detectable syntrophin by IHC in DMD muscle (4, 27, 69) . However, the authors demonstrate normal levels of total syntrophin by immunoblot in dystrophin-deficient muscle (4), consistent with our findings. FIGURE 7 . Expression levels of a1-and b1-syntrophin are altered in patients with denervation disorders. Immunoblot analysis of (A) a1-syntrophin (a1-SYN) and (B) b1-syntrophin (b1-SYN) in 4 age-matched control skeletal muscle biopsies (C 1 -C 4 ), giant axonal neuropathy (G) patient, amyotrophic lateral sclerosis (A) patient, and three biopsies from patients with spinal muscular atrophy (S 1a -S 2 ). S 1a and S 1b are different biopsies from the same patient; S 1a contains a mixture of innervated and denervated fibers while S 1b contains mostly denervated fibers. Coomassie staining of the membrane demonstrates myosin loading. The proportion of fast fibers in samples analyzed for b1-syntrophin expression is shown using an antibody recognizing fast myosin (MY32). MY32 also recognizes nMyHC.
Denervation Specifically Affects Expression of the Syntrophin-Dystrobrevin Subcomplex
In denervated muscle samples, expression of the syntrophin-dystrobrevin subcomplex was significantly altered. a1-Syntrophin, aDB1, and aDB2 were lost from the sarcolemmal membrane of denervated fibers. b1-Syntrophin, normally restricted to fast fibers, was upregulated in response to denervation and stained the sarcolemmal membrane of all fibers. Upregulation and loss of fiber-type specificity of b1-syntrophin was accompanied by re-expression of the nAChR-g subunit and neonatal MyHC in denervated fibers. These results mirror changes in b1-syntrophin expression levels and distribution during development and in dystrophinopathy. The localization of b2-syntrophin was unaffected by denervation, perhaps because it is normally restricted to slow fibers, which correspond to the normal, innervated fibers in these patients. In contrast, immunostaining of all other members of the dystrophin-associated protein complex (dystrophin, dystroglycans, laminin a2, all sarcoglycans and sarcospan) was normal in both the large innervated fibers and the atrophied denervated fibers, in all patients studied. Utrophin immunostaining remained localized to the NMJ in normal innervated fibers, similar to controls, and exhibited no increased expression at the membrane of the denervated fibers. These findings suggest that innervation uniquely governs assembly of the syntrophins and a-dystrobrevin within the dystrophin complex.
The specific effect of denervation on the syntrophindystrobrevin subcomplex may be a consequence of their dual role(s) at the sarcolemmal membrane and postsynaptic region of the NMJ. Loss of a1-syntrophin from the sarcolemmal membrane secondary to denervation is supported by previous observations using a generic syntrophin antibody (mAb SYN1351) in 6-week denervated rat diaphragm, which showed syntrophin loss from the extrajunctional sarcolemmal membrane (1). b2-Syntrophin has been shown to contain an N-box motif within its putative promoter region (8, 70) . This motif is also present in the nAChR-d gene promoter and is thought to impart preferential transcription within nuclei underneath NMJs (71) . Thus, the syntrophin-dystrobrevin subcomplex may be subject to regulation mediated through synaptic activity and the effects of signaling molecules coming from the motor nerve terminal (agrin, heregulin, and various trophic factors).
A previous study by our laboratory identified a group of patients with congenital myopathy or dystrophy of unknown etiology with isolated abnormalities of the syntrophindystrobrevin subcomplex (39) ; staining for dystrophin, laminin a2, the sarcoglycans, and other members of the DAPC was normal. In the current study, we have demonstrated that denervation specifically affects the expression and localization of the syntrophin-dystrobrevin subcomplex, while dystrophin and other components of the DAPC remain normally localized. These observations suggest that a neuropathic process may underlie disease pathogenesis in some patients with muscle histopathology suggestive of a primary myopathic or dystrophic disorder.
In conclusion, the syntrophins and a-dystrobrevin isoforms have distinct expression patterns during development and are differentially affected by loss of dystrophin anchorage and denervation. b1-Syntrophin is the predominant syntrophin isoform expressed during development, when a1-syntrophin is not present at the sarcolemma. b1-Syntrophin appears to play a ''compensatory'' role (upregulation and expression in all fibers) in both dystrophinopathy and denervation, in response to loss of a1-syntrophin. Upregulation of b1-syntrophin in response to loss of a1-syntrophin mimics ''compensatory'' upregulation of utrophin in response to decreased levels of dystrophin, which is also observed during development and in dystrophinopathies. Furthermore, denervation specifically affects the expression and localization of the syntrophins and a-dystrobrevin within the DAPC, suggesting that the subcomplex may be independently recruited and assembled at the sarcolemma and/or NMJ, and is subject to regulation through neuromuscular transmission.
